Systemic Meglumine Antimoniate in Acute Cutaneous Leishmaniasis: Children versus Adults
Some studies showed that children have a lower response to systemic use of pentavalent antimoniate than adults. We aimed to evaluate the response rate to Glucantime therapy in children and compare it with adults. One hundred and twelve patients with acute cutaneous leishmaniasis: (ACL) were divided...
Gespeichert in:
Veröffentlicht in: | The American journal of tropical medicine and hygiene 2011-04, Vol.84 (4), p.539-542 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 542 |
---|---|
container_issue | 4 |
container_start_page | 539 |
container_title | The American journal of tropical medicine and hygiene |
container_volume | 84 |
creator | LAYEGH, Pouran RAHSEPAR, Sara AMIR ALI RAHSEPAR |
description | Some studies showed that children have a lower response to systemic use of pentavalent antimoniate than adults. We aimed to evaluate the response rate to Glucantime therapy in children and compare it with adults. One hundred and twelve patients with acute cutaneous leishmaniasis: (ACL) were divided into two equal groups of adults (> 15 yrs) and children (≤ 15 yrs). They received meglumine antimoniate; 20 mg/kg/day for 20 days, their improvement rate was evaluated 20 and 45 days after treatment. Per-protocol analysis showed a significantly lower response in the children group 20 and 45 days after initiation of the treatment (P = 0.0001, 95% confidence interval [CI] = 0.190 [0.079-0.456]/P = 0.0051, 95% CI = 0.317 [0.140-0.717], respectively). Moreover, after intention-to-treat analysis, the same results were seen in the younger group 20 and 45 days after treatment (P = 0.0003, 95% CI = 0.228 [0.098-0.528]/P = 0.0132, 95% CI = 0.382 [0.177-0.825], respectively). According to our results, systemic Glucantime has lower efficacy in treating ACL in children than adults. |
doi_str_mv | 10.4269/ajtmh.2011.10-0002 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3062445</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1014101049</sourcerecordid><originalsourceid>FETCH-LOGICAL-c513t-e9ab1d14d75439f3813d6678a023adf383db8cc59cbd69f278d1fb9e0d4dedf83</originalsourceid><addsrcrecordid>eNp9kUFP3DAQhS3UChbKH-CAcqnaSxaP7Tgxh0qrVWmRFvXQVj1aju2wRokDtoPEv8fpbmm59GDZM--bJ48eQmeAl4xwcaHu0rBdEgywBFxijMkBWgCreQmcVW_QYm6VgtP6CB3HeIcxNATgEB0RYDyLfIF-fX-KyQ5OFzf2tp8G522x8skNo3cq2cL5YqWn_FhPSXk7TrHYWBe3g8p6dPGyWG9db4L1xaMNMcsrM_UpvkNvO9VHe7q_T9DPq88_1l_Lzbcv1-vVptQV0FRaoVowwExdMSo62gA1nNeNwoQqk2tq2kbrSujWcNGRujHQtcJiw4w1XUNP0Ked7_3UDtZo61NQvbwPblDhSY7KydeKd1t5Oz5KijlhrMoGH_YGYXyYbExycFHbvt9tKxuOQYBgPJMf_0sCBpYPZiKjZIfqMMYYbPfyIcByzk7-zk7O2c2tOag8dP7vKi8jf8LKwPs9oKJWfReU1y7-5RjmIASlz5AdpSw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1014101049</pqid></control><display><type>article</type><title>Systemic Meglumine Antimoniate in Acute Cutaneous Leishmaniasis: Children versus Adults</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>LAYEGH, Pouran ; RAHSEPAR, Sara ; AMIR ALI RAHSEPAR</creator><creatorcontrib>LAYEGH, Pouran ; RAHSEPAR, Sara ; AMIR ALI RAHSEPAR</creatorcontrib><description>Some studies showed that children have a lower response to systemic use of pentavalent antimoniate than adults. We aimed to evaluate the response rate to Glucantime therapy in children and compare it with adults. One hundred and twelve patients with acute cutaneous leishmaniasis: (ACL) were divided into two equal groups of adults (> 15 yrs) and children (≤ 15 yrs). They received meglumine antimoniate; 20 mg/kg/day for 20 days, their improvement rate was evaluated 20 and 45 days after treatment. Per-protocol analysis showed a significantly lower response in the children group 20 and 45 days after initiation of the treatment (P = 0.0001, 95% confidence interval [CI] = 0.190 [0.079-0.456]/P = 0.0051, 95% CI = 0.317 [0.140-0.717], respectively). Moreover, after intention-to-treat analysis, the same results were seen in the younger group 20 and 45 days after treatment (P = 0.0003, 95% CI = 0.228 [0.098-0.528]/P = 0.0132, 95% CI = 0.382 [0.177-0.825], respectively). According to our results, systemic Glucantime has lower efficacy in treating ACL in children than adults.</description><identifier>ISSN: 0002-9637</identifier><identifier>EISSN: 1476-1645</identifier><identifier>DOI: 10.4269/ajtmh.2011.10-0002</identifier><identifier>PMID: 21460006</identifier><identifier>CODEN: AJTHAB</identifier><language>eng</language><publisher>Deerfield, IL: American Society of Tropical Medecine and Hygiene</publisher><subject>Adolescent ; Adult ; Age Factors ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiparasitic agents ; Antiprotozoal Agents - administration & dosage ; Antiprotozoal Agents - therapeutic use ; Biological and medical sciences ; Child ; Child, Preschool ; Female ; Human protozoal diseases ; Humans ; Infectious diseases ; Leishmaniasis, Cutaneous - drug therapy ; Leshmaniasis ; Male ; Medical sciences ; Medication Adherence ; Meglumine - administration & dosage ; Meglumine - therapeutic use ; Organometallic Compounds - administration & dosage ; Organometallic Compounds - therapeutic use ; Parasitic diseases ; Pharmacology. Drug treatments ; Protozoal diseases ; Young Adult</subject><ispartof>The American journal of tropical medicine and hygiene, 2011-04, Vol.84 (4), p.539-542</ispartof><rights>2015 INIST-CNRS</rights><rights>The American Society of Tropical Medicine and Hygiene 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c513t-e9ab1d14d75439f3813d6678a023adf383db8cc59cbd69f278d1fb9e0d4dedf83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062445/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062445/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24061993$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21460006$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LAYEGH, Pouran</creatorcontrib><creatorcontrib>RAHSEPAR, Sara</creatorcontrib><creatorcontrib>AMIR ALI RAHSEPAR</creatorcontrib><title>Systemic Meglumine Antimoniate in Acute Cutaneous Leishmaniasis: Children versus Adults</title><title>The American journal of tropical medicine and hygiene</title><addtitle>Am J Trop Med Hyg</addtitle><description>Some studies showed that children have a lower response to systemic use of pentavalent antimoniate than adults. We aimed to evaluate the response rate to Glucantime therapy in children and compare it with adults. One hundred and twelve patients with acute cutaneous leishmaniasis: (ACL) were divided into two equal groups of adults (> 15 yrs) and children (≤ 15 yrs). They received meglumine antimoniate; 20 mg/kg/day for 20 days, their improvement rate was evaluated 20 and 45 days after treatment. Per-protocol analysis showed a significantly lower response in the children group 20 and 45 days after initiation of the treatment (P = 0.0001, 95% confidence interval [CI] = 0.190 [0.079-0.456]/P = 0.0051, 95% CI = 0.317 [0.140-0.717], respectively). Moreover, after intention-to-treat analysis, the same results were seen in the younger group 20 and 45 days after treatment (P = 0.0003, 95% CI = 0.228 [0.098-0.528]/P = 0.0132, 95% CI = 0.382 [0.177-0.825], respectively). According to our results, systemic Glucantime has lower efficacy in treating ACL in children than adults.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiparasitic agents</subject><subject>Antiprotozoal Agents - administration & dosage</subject><subject>Antiprotozoal Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Female</subject><subject>Human protozoal diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Leishmaniasis, Cutaneous - drug therapy</subject><subject>Leshmaniasis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medication Adherence</subject><subject>Meglumine - administration & dosage</subject><subject>Meglumine - therapeutic use</subject><subject>Organometallic Compounds - administration & dosage</subject><subject>Organometallic Compounds - therapeutic use</subject><subject>Parasitic diseases</subject><subject>Pharmacology. Drug treatments</subject><subject>Protozoal diseases</subject><subject>Young Adult</subject><issn>0002-9637</issn><issn>1476-1645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUFP3DAQhS3UChbKH-CAcqnaSxaP7Tgxh0qrVWmRFvXQVj1aju2wRokDtoPEv8fpbmm59GDZM--bJ48eQmeAl4xwcaHu0rBdEgywBFxijMkBWgCreQmcVW_QYm6VgtP6CB3HeIcxNATgEB0RYDyLfIF-fX-KyQ5OFzf2tp8G522x8skNo3cq2cL5YqWn_FhPSXk7TrHYWBe3g8p6dPGyWG9db4L1xaMNMcsrM_UpvkNvO9VHe7q_T9DPq88_1l_Lzbcv1-vVptQV0FRaoVowwExdMSo62gA1nNeNwoQqk2tq2kbrSujWcNGRujHQtcJiw4w1XUNP0Ked7_3UDtZo61NQvbwPblDhSY7KydeKd1t5Oz5KijlhrMoGH_YGYXyYbExycFHbvt9tKxuOQYBgPJMf_0sCBpYPZiKjZIfqMMYYbPfyIcByzk7-zk7O2c2tOag8dP7vKi8jf8LKwPs9oKJWfReU1y7-5RjmIASlz5AdpSw</recordid><startdate>20110401</startdate><enddate>20110401</enddate><creator>LAYEGH, Pouran</creator><creator>RAHSEPAR, Sara</creator><creator>AMIR ALI RAHSEPAR</creator><general>American Society of Tropical Medecine and Hygiene</general><general>The American Society of Tropical Medicine and Hygiene</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7U2</scope><scope>C1K</scope><scope>F1W</scope><scope>H95</scope><scope>H97</scope><scope>L.G</scope><scope>M7N</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20110401</creationdate><title>Systemic Meglumine Antimoniate in Acute Cutaneous Leishmaniasis: Children versus Adults</title><author>LAYEGH, Pouran ; RAHSEPAR, Sara ; AMIR ALI RAHSEPAR</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c513t-e9ab1d14d75439f3813d6678a023adf383db8cc59cbd69f278d1fb9e0d4dedf83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiparasitic agents</topic><topic>Antiprotozoal Agents - administration & dosage</topic><topic>Antiprotozoal Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Female</topic><topic>Human protozoal diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Leishmaniasis, Cutaneous - drug therapy</topic><topic>Leshmaniasis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medication Adherence</topic><topic>Meglumine - administration & dosage</topic><topic>Meglumine - therapeutic use</topic><topic>Organometallic Compounds - administration & dosage</topic><topic>Organometallic Compounds - therapeutic use</topic><topic>Parasitic diseases</topic><topic>Pharmacology. Drug treatments</topic><topic>Protozoal diseases</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LAYEGH, Pouran</creatorcontrib><creatorcontrib>RAHSEPAR, Sara</creatorcontrib><creatorcontrib>AMIR ALI RAHSEPAR</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The American journal of tropical medicine and hygiene</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LAYEGH, Pouran</au><au>RAHSEPAR, Sara</au><au>AMIR ALI RAHSEPAR</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Systemic Meglumine Antimoniate in Acute Cutaneous Leishmaniasis: Children versus Adults</atitle><jtitle>The American journal of tropical medicine and hygiene</jtitle><addtitle>Am J Trop Med Hyg</addtitle><date>2011-04-01</date><risdate>2011</risdate><volume>84</volume><issue>4</issue><spage>539</spage><epage>542</epage><pages>539-542</pages><issn>0002-9637</issn><eissn>1476-1645</eissn><coden>AJTHAB</coden><abstract>Some studies showed that children have a lower response to systemic use of pentavalent antimoniate than adults. We aimed to evaluate the response rate to Glucantime therapy in children and compare it with adults. One hundred and twelve patients with acute cutaneous leishmaniasis: (ACL) were divided into two equal groups of adults (> 15 yrs) and children (≤ 15 yrs). They received meglumine antimoniate; 20 mg/kg/day for 20 days, their improvement rate was evaluated 20 and 45 days after treatment. Per-protocol analysis showed a significantly lower response in the children group 20 and 45 days after initiation of the treatment (P = 0.0001, 95% confidence interval [CI] = 0.190 [0.079-0.456]/P = 0.0051, 95% CI = 0.317 [0.140-0.717], respectively). Moreover, after intention-to-treat analysis, the same results were seen in the younger group 20 and 45 days after treatment (P = 0.0003, 95% CI = 0.228 [0.098-0.528]/P = 0.0132, 95% CI = 0.382 [0.177-0.825], respectively). According to our results, systemic Glucantime has lower efficacy in treating ACL in children than adults.</abstract><cop>Deerfield, IL</cop><pub>American Society of Tropical Medecine and Hygiene</pub><pmid>21460006</pmid><doi>10.4269/ajtmh.2011.10-0002</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-9637 |
ispartof | The American journal of tropical medicine and hygiene, 2011-04, Vol.84 (4), p.539-542 |
issn | 0002-9637 1476-1645 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3062445 |
source | MEDLINE; PubMed Central; Alma/SFX Local Collection; EZB Electronic Journals Library |
subjects | Adolescent Adult Age Factors Antibiotics. Antiinfectious agents. Antiparasitic agents Antiparasitic agents Antiprotozoal Agents - administration & dosage Antiprotozoal Agents - therapeutic use Biological and medical sciences Child Child, Preschool Female Human protozoal diseases Humans Infectious diseases Leishmaniasis, Cutaneous - drug therapy Leshmaniasis Male Medical sciences Medication Adherence Meglumine - administration & dosage Meglumine - therapeutic use Organometallic Compounds - administration & dosage Organometallic Compounds - therapeutic use Parasitic diseases Pharmacology. Drug treatments Protozoal diseases Young Adult |
title | Systemic Meglumine Antimoniate in Acute Cutaneous Leishmaniasis: Children versus Adults |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T02%3A34%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Systemic%20Meglumine%20Antimoniate%20in%20Acute%20Cutaneous%20Leishmaniasis:%20Children%20versus%20Adults&rft.jtitle=The%20American%20journal%20of%20tropical%20medicine%20and%20hygiene&rft.au=LAYEGH,%20Pouran&rft.date=2011-04-01&rft.volume=84&rft.issue=4&rft.spage=539&rft.epage=542&rft.pages=539-542&rft.issn=0002-9637&rft.eissn=1476-1645&rft.coden=AJTHAB&rft_id=info:doi/10.4269/ajtmh.2011.10-0002&rft_dat=%3Cproquest_pubme%3E1014101049%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1014101049&rft_id=info:pmid/21460006&rfr_iscdi=true |